[1] Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, and Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8): 801-810.
[2] Gofton TE, Young GB. Sepsis-associated encephalopathy. Nat Rev Neurol. 2012; 8(10): 557-66.
[3] Zhang LN, Wang XT, Ai YH, Guo QL, Huang L, Liu ZY, and Yao B. Epidemiological features and risk factors of sepsis-associated encephalopathy in intensive care unit patients: 2008–2011. Chin Med J (Engl). 2012; 125(5): 828–831.
[4] Comim CM, Constantino LC, Barichello T, Streck EL, Quevedo J, and Dal-Pizzol F. Cognitive impairment in the septic brain. Curr Neurovasc Res. 2009; 6(3): 194–203.
[5] Robba C, Crippa IA, and Taccone FS. Septic Encephalopathy. Curr Neurol Neurosci Rep. 2018; 18(12): 82.
[6] Liu W, Guo J, Mu J, Tian L, and Zhou D. Rapamycin Protects Sepsis-Induced Cognitive Impairment in Mouse Hippocampus by Enhancing Autophagy. Cell Mol Neurobiol. 2017; 37(7): 1195-1205.
[7] Yao B, Zhang LN, Ai YH, Liu ZY, and Huang L. Serum S100β is a better biomarker than neuron-specific enolase for sepsis-associated encephalopathy and determining its prognosis: a prospective and observational study. Neurochem Res. 2014; 39(7): 1263-1269.
[8] Rothermundt M, Peters M, Prehn J, and Arolt V. S100B in brain damage and neurodegeneration. Microsc Res Tech. 2003; 60(6): 614–632.
[9] Huttunen H J,Kuja-Panula J,Sorci G, Agneletti AL, Donato R, and Rauvala H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem. 2000; 275(51): 40096-40105.
[10] Piva S, McCreadie VA, and Latronico N. Neuroinflammation in sepsis: sepsis associated delirium. Cardiovasc Hematol Disord Drug Targets. 2015; 15(1): 10-8.
[11] Fernandes RA, Ingle AB. Arundic acid a potential neuroprotective agent: biological development and syntheses. Curr Med Chem. 2013; 20(18): 2315-29.
[12] Hanada M, Shinjo R, Miyagi M, Yasuda T, Tsutsumi K, Sugiura Y, Imagama S, Ishiguro N, and Matsuyama Y. Arundic acid (ONO-2506) inhibits secondary injury and improves motor function in rats with spinal cord injury. J Neurol Sci. 2014; 337(1-2): 186-92.
[13] Ishiguro H, Kaito T, Hashimoto K, Kushioka J, Okada R, Tsukazaki H, Kodama J, Bal Z, Ukon Y, Takenaka S, Makino T, Sakai Y, and Yoshikawa H. Administration of ONO-2506 suppresses neuropathic pain after spinal cord injury by inhibition of astrocytic activation. Spine J. 2019; 19(8): 1434-1442.
[14] Ohtani R, Tomimoto H, Wakita H, Kitaguchi H, Nakaji K, and Takahashi R. Expression of S100 protein and protective effect of arundic acid on the rat brain in chronic cerebral hypoperfusion. Brain Res. 2007; 1135(1): 195-200.
[15] Higashino H , Niwa A, Satou T, Ohta Y, Hashimoto S, Tabuchi M, and Ooshima K. Immunohistochemical analysis of brain lesions using S100B and glial fibrillary acidic protein antibodies in arundic acid- (ONO-2506) treated stroke-prone spontaneously hypertensive rats. J Neural Transm (Vienna). 2009; 116(10): 1209-1219.
[16] Kato H, Araki T, Imai Y, Takahashi A, and Itoyama Y. Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease. J Neurol Sci. 2003; 208(1-2): 9-15.
[17] Wajima D, Nakagawa I, Nakase H, and Yonezawa T. Neuroprotective effect of suppression of astrocytic activation by arundic acid on brain injuries in rats with acute subdural hematomas. Brain Res. 2013; 1519: 127-135.
[18] Oki C, Watanabe Y, Yokoyama H, Shimoda T, Kato H, and Araki T. Delayed treatment with arundic acid reduces the MPTP-induced neurotoxicity in mice. Cell Mol Neurobiol. 2008; 28(3): 417-430.
[19] Tateishi N, Mori T, Kagamiishi Y, Satoh S, Katsube N, Morikawa E, Morimoto T, Matsui T, and Asano T. Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part II: suppression of astrocytic activation by a novel agent (R)-(-)-2-propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurologic deficits. J Cereb Blood Flow Metab. 2002; 22(6): 723-34.
[20] Pettigrew LC, Kasner SE, Gorman M, Atkinson RP, Funakoshi Y, and Ishibashi H. Effect of arundic acid on serum S-100beta in ischemic stroke. J Neurol Sci. 2006; 251(1-2): 57-61.
[21] Pettigrew LC, Kasner SE, Albers GW, Gorman M, Grotta JC, Sherman DG, Funakoshi Y, and Ishibashi H. Safety and tolerability of arundic acid in acute ischemic stroke. J Neurol Sci. 2006; 251(1-2): 50-56.
[22] Heming N, Mazeraud A, Verdonk F, Bozza FA, Chrétien F, and Sharshar T. Neuroanatomy of sepsis-associated encephalopathy. Crit Care. 2017; 21(1): 65.
[23] Bozza FA, Garteiser P, Oliveira MF, Doblas S, Cranford R, Saunders D, Jones I, Towner RA, and Castro-Faria-Neto HC. Sepsis-associated encephalopathy: a magnetic resonance imaging and spectroscopy study. J Cereb Blood Flow Metab. 2010; 30(2): 440-448.
[24] Sun F, Si Y, Bao H, Xu Y, Pan X, Zeng L, and Jing L. Regulation of Sirtuin 3-Mediated Deacetylation of Cyclophilin D Attenuated Cognitive Dysfunction Induced by Sepsis-Associated Encephalopathy in Mice. Cell Mol Neurobiol. 2017; 37(8): 1457-1464.
[25] Comim CM, Barichello T, and Grandgirard D. Caspase-3 mediates in part hippocampal apoptosis in sepsis. Mol Neurobiol. 2013; 47(1): 394-398.
[26] Lukic IK, Humpert PM, Nawroth PP, and Bierhaus A. The RAGE pathway: activation and perpetuation in the pathogenesis of diabetic neuropathy. Ann N Y Acad Sci. 2008; 1126: 76-80.
[27] Gasparotto J, Ribeiro CT, Bortolin RC, Somensi N, Fernandes HS, Teixeira AA, Guasselli MOR, Agani CAJO, Souza NC, Grings M, Leipnitz G, Gomes HM, de Bittencourt Pasquali MA, Dunkley PR, Dickson PW, Moreira JCF, and Gelain DP. Anti-RAGE antibody selectively blocks acute systemic inflammatory responses to LPS in serum, liver, CSF and striatum. Brain Behav Immun. 2017; 62: 124-136.
[28] Mazarati A, Maroso M, Iori V, Vezzani A, and Carli M. High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and Receptor for Advanced Glycation End Products. Exp Neurol. 2011; 232(2): 143-148.
[29] Villarreal A, Aviles Reyes RX, Angelo MF, Reines AG, and Ramos AJ. S100B alters neuronal survival and dendrite extension via RAGE-mediated NF-κB signaling. J Neurochem. 2011; 117(2): 321-332.
[30] Karki P, Hong P, Johnson J Jr, Pajarillo E, Son DS, Aschner M, and Lee EY. Arundic Acid Increases Expression and Function of Astrocytic Glutamate Transporter EAAT1 Via the ERK, Akt, and NF-κB Pathways. Mol Neurobiol. 2018; 55(6): 5031-5046.